---
title: "Takeda Pharmaceutical Company: Q1 FY2026 delivered robust core revenue growth, driven by new launches and disciplined investment"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294315248.md"
description: "Q1 FY2026 core revenue grew 10.2% YoY (flat at CER), with strong performance from new launches and core brands offsetting mature portfolio declines. Investments in transformative medicines and R&D continue, with full-year guidance reaffirmed and a focus on deleveraging and dividend growth.Original document: Takeda Pharmaceutical Co. Ltd. [4502] Slides Release — Jul. 30 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-07-30T06:51:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294315248.md)
  - [en](https://longbridge.com/en/news/294315248.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294315248.md)
generator: "portal-rs"
---

# Takeda Pharmaceutical Company: Q1 FY2026 delivered robust core revenue growth, driven by new launches and disciplined investment

Q1 FY2026 core revenue grew 10.2% YoY (flat at CER), with strong performance from new launches and core brands offsetting mature portfolio declines. Investments in transformative medicines and R&D continue, with full-year guidance reaffirmed and a focus on deleveraging and dividend growth.

Original document: Takeda Pharmaceutical Co. Ltd. \[4502\] Slides Release — Jul. 30 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [TAK.US](https://longbridge.com/en/quote/TAK.US.md)
- [4502.JP](https://longbridge.com/en/quote/4502.JP.md)

## Related News & Research

- [Takeda adds boxed warning on ADZYNMA over risk of neutralizing antibodies to ADAMTS13](https://longbridge.com/en/news/296794493.md)
- [Takeda’s Orzeyful secured Japan MHLW approval for narcolepsy type 1](https://longbridge.com/en/news/296890461.md)
- [Takeda says Japan approves ORZEYFUL to treat narcolepsy type 1 in adults](https://longbridge.com/en/news/296745287.md)
- [ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1 | TAK Stock News](https://longbridge.com/en/news/296745786.md)
- [Microsoft employees reveal how much cash they're burning on AI](https://longbridge.com/en/news/296828490.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**